Back to search

Switzerland· 57872001

Vectibix 100 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung

A panitumumab product containing panitumumabum, registered in Switzerland by Amgen Switzerland AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01FE02

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedVectibix 100 mg/5 ml, Konzentrat zur …ATCL01FE02REGISTER NO.57872001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Panitumumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FE02 (panitumumab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Panitumumab · ATC L01FE02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
panitumumabum
Manufacturer
Amgen Switzerland AG
Country
Switzerland (CH)
ATC code
L01FE02
ATC class
Panitumumab
Defined daily dose
30 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680578720017
    Durchstf 5 ml
    CHF 426.9

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

27 interactions on record for panitumumab.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Panitumumab · interactions on record

27 records

  • 14 severe
  • 13 moderate

Most severe, free to view

  • AmiodaroneC01BD01severe
  • DofetilideC01BD04severe
  • DronedaroneC01BD07severe
  • IrinotecanL01CE02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Panitumumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All panitumumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Vectibix
  • Norway · Vectibix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/02942966-169e-4328-bd2d-8442553144b6
GET /v1/drugs/02942966-169e-4328-bd2d-8442553144b6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "panitumumabum 100 mg",
  "valid_from": "2010-05-01",
  "limitations": "[{\"description\":\"Nur nach vorgängiger Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes:<br>\\nZur Behandlung von Patienten mit metastasierendem kolorektalem Karzinom mit RAS-Wildtyp<br>\\n-\\tIn der First-Line-Therapie in Kombination mit FOLFOX oder FOLFIRI. <br>\\n-\\tIn der Second-Line-Therapie in Kombination mit einer Irinotecan-haltigen Chemotherapie. <br>\\n-\\tAls Monotherapie, wenn Therapien mit Fluoropyrimidin-, Oxaliplatin- und Irinotecan-haltigen Chemotherapien versagt haben oder nicht durchführbar waren.<br>\\nIm Falle einer Progression ist die Vectibix-Behandlung abzubrechen.\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2019-12-01\"}]",
  "galenic_form": "Inf Konz 100 mg/5ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2010-05-01",
  "self_retention_pct": 10
}

See everything about panitumumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.